Lexington Biosciences (LXGTF) Ratios
Lexington Biosciences Ratios
LXGTF's free cash flow for Q3 2024 was $0.00. For the 2024 fiscal year, LXGTF's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Quick Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 |
| Solvency Ratio | -0.02 | 0.21 | -0.01 | 0.30 | -1.21 |
| Operating Cash Flow Ratio | 0.00 | -0.00 | -0.01 | -0.21 | -0.20 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Net Current Asset Value | $ -988.79K | $ -811.41K | $ -1.82M | $ -1.49M | $ -1.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 65.77 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.81 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -4.30 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 0.00 | 0.00 | -0.00 | -0.02 | -0.01 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -1.19 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -4.42 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 11.60 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.25 |
| Net Debt to EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -0.72 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.22% | 0.10% | 100.00% | 0.10% | 100.00% |
| EBT Per EBIT | 112.03% | 101.43% | 103.71% | 104.60% | 238.00% |
| Return on Assets (ROA) | 0.00% | 0.00% | -48831.17% | -1.74% | -9901.58% |
| Return on Equity (ROE) | 17.94% | 0.02% | 17.83% | 0.03% | 122.14% |
| Return on Capital Employed (ROCE) | 15.98% | 21.38% | 17.19% | 30.74% | 51.32% |
| Return on Invested Capital (ROIC) | 15.98% | 21.38% | 17.19% | 30.74% | 272.03% |
| Return on Tangible Assets | 0.00% | 0.00% | -48831.17% | -1.74% | -9901.58% |
| Earnings Yield | -7553.41% | -470.69% | -93420.25% | -0.04% | -1746.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.00 | -0.00 | -0.00 | -0.03 | -0.06 |
| Free Cash Flow Per Share | 0.00 | -0.00 | -0.00 | -0.03 | -0.06 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | 0.00% | -1785.93% | -7770.93% | -25.46% | -289.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.01 | -0.21 | -0.00 | -2661.12 | -0.06 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.00 | -0.00 | -0.00 | -0.85 | -0.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 0.00 | -0.06 | -0.01 | -3.93 | -0.35 |
| Price-to-Operating Cash Flow Ratio | 0.00 | -0.06 | -0.01 | -3.93 | -0.35 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.00 | 26.61 | 0.00 |
| Enterprise Value Multiple | 0.00 | 0.00 | 0.00 | 0.00 | -0.79 |
| Enterprise Value | 2.35K | 37 | -316 | 1.25M | 903.36K |
| EV to EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -0.79 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.00 | -0.06 | 0.01 | -3.84 | -4.30 |
| EV to Operating Cash Flow | 0.00 | -0.06 | 0.01 | -3.84 | -4.30 |
| Tangible Book Value Per Share | -0.06 | -0.03 | -0.07 | -0.12 | -0.27 |
| Shareholders’ Equity Per Share | -0.06 | -0.03 | -0.07 | -0.12 | -0.27 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.00 | -0.01 | -0.00 | -0.34 |
| Tax Burden | 1.00 | 0.00 | 1.00 | 0.00 | 1.00 |
| Interest Burden | 1.12 | 1.01 | 1.04 | 1.05 | 1.11 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.00 | 0.00 | 0.08 | 0.68 | 0.17 |
Currency in CAD